RxDoctor Payments Data

Alanna Beckman, MD

Family Medicine · Lincoln, NENPI 1457648040

Payments from drug & device makers

$1,139in general payments, 2019–2025

Across 83 payments — averaging $13.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$626
  • AbbVie$97
  • Novo Nordisk$91
  • Pfizer$51
  • Biohaven Pharmaceutical Holding Company Ltd.$32
  • Boehringer Ingelheim$29
  • plus $213 from 13 others

What the payments were for

  • Food & beverage$1,139100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,139 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$6,706
Medicare patients
155
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$101,699
XareltoRivaroxaban112$76,198
EliquisApixaban164$75,018
JardianceEmpagliflozin110$71,585
TrulicityDulaglutide21$23,560
FarxigaDapagliflozin Propanediol36$22,079
RybelsusSemaglutide16$19,831
MyrbetriqMirabegron57$18,769
ArexvyRsvpref3 Antigen/As01e/Pf55$17,146
Fentanyl133$12,332
Breo ElliptaFluticasone/Vilanterol18$9,438
Combivent RespimatIpratropium/Albuterol Sulfate11$9,113
RestasisCyclosporine23$7,925
Potassium Chloride353$7,483
LinzessLinaclotide13$7,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$91$121,530123 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$29$86,214142 claims
PfizerEliquis$51$75,018164 claims
GSKArexvy, Breo Ellipta, Shingrix$13$29,90788 claims
Lilly USA, LLCTrulicity$27$23,56021 claims
AbbVieRestasis, Linzess$97$15,14536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →